Sort
30,917 grants matching “tumor microenvironment”
Optimizing immunoradiotherapy for HNSCC
$692,235Joseph A Califano · University Of California, San Diego · R01 · FY2023 · CA
Project 2: : Systematic discovery of cell-extrinsic mechanisms of cancer drug resistance
$692,202Alex K Shalek · Massachusetts Institute Of Technology · U54 · FY2020 · CA
Personalized Adoptive T-cell Therapy for AML
$692,077David E Avigan · Beth Israel Deaconess Medical Center · R01 · FY2024 · CA
Interdisciplinary Epidemiologic Consortium to Investigate T-cell Response in Colorectal Cancer
$692,007Ulrike Peters · Fred Hutchinson Cancer Center · R01 · FY2023 · CA
(PQC4) Habitats in Prostate Cancer
$692,000Robert J Gillies · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2015 · CA
Cancer Center Support Grant
$692,000Nancy E Davidson · University Of Pittsburgh At Pittsburgh · P30 · FY2015 · CA
Role of FACT in ZFTA-RelA fusion driven ependymoma
$691,965Monica Venere · Ohio State University · R01 · FY2025 · CA
TARGETING THE TUMOR MICROENVIRONMENT AND METASTATIC NICHE IN BREAST CANCER
$691,732University Of Texas Health Science Center At Houston · · FY2020 · Defense Health Agency
Angiogenesis and Tumor Growth
$691,693Giovanna Tosato · Division Of Clinical Sciences - Nci · ZIA · FY2019 · CA
Molecular Imaging and Theranostics of Cancer
$691,623Zaver M Bhujwalla · Johns Hopkins University · R35 · FY2017 · CA
Creation of in vivo active chemical probes for CAMKK2 to treat cancer
$691,617David Harold Drewry · Univ Of North Carolina Chapel Hill · R01 · FY2017 · CA
Project Title: Low-dose erlotinib and mesalamine for prevention of colitis-associated colorectal cancer (CAC)
$691,578Eduardo Vilar Sanchez · University Of Tx Md Anderson Can Ctr · N01 · FY2025 · CA
Spatial genomic tools to interrogate T cell clonotypes, tumor clones and the microenvironment
$691,271Fei Chen · Broad Institute, Inc. · R01 · FY2023 · CA
Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy
$691,118Laura B. Oswald · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · CA
Smart and self-reporting clinical nano carriers for drug delivery
$691,044Jan Grimm · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
Optimizing anti-wild-type IDH1 therapy in pancreatic cancer
$690,929Jordan M Winter · Case Western Reserve University · R01 · FY2024 · CA
Re-engineering differential regulation of ferroptosis in melanoma microenvironment
$690,908Yuri Bunimovich · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Multiscale Modeling of Bone Environment Responses to Metastatic Prostate Cancer
$690,824David Basanta Gutierrez · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2017 · CA
Pathomic Predictors of Prostate Cancer Progression
$690,744Parag Kumar Mallick · Stanford University · R01 · FY2024 · CA
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity
$690,624Edgar G. Engleman · Stanford University · R01 · FY2024 · CA
Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy
$690,260Laura B. Oswald · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
$690,258Diane M Simeone · New York University School Of Medicine · R01 · FY2021 · CA
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer
$689,955Saul Priceman · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Assessment of germline variants associated with immune-related adverse events following immune checkpoint inhibitors
$689,934Toni Choueiri · Dana-Farber Cancer Inst · R01 · FY2024 · CA
Smart and self-reporting clinical nano carriers for drug delivery
$689,833Jan Grimm · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA